Physician profile
Miguel A Ayala
NPI 1538446448
$123,659.81
in general payments reported to CMS, 2019-2025
6 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16K · 2022: $44K · 2023: $26K · 2024: $18K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Travel and Lodging: $11K · Food and Beverage: $5,838 · Consulting Fee: $1,294 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,030.00 |
| Travel and Lodging | $11,100.60 |
| Food and Beverage | $5,837.93 |
| Consulting Fee | $1,293.75 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $98,476.84 | 2021-2025 | |
| Gilead Sciences, INC. | $23,841.49 | 2021-2023 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $987.32 | 2021-2023 | Xifaxan |
| Lilly USA, LLC | $162.57 | 2023 | Mounjaro |
| Insulet Corporation | $111.71 | 2022-2023 | Omnipod |
| Novo Nordisk INC | $79.88 | 2021-2023 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miguel Ayala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.